Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Rien Ritawidya ^1,2 , Hendris Wongso ^1,2 , Nurmaya Effendi ³ , Anung Pujiyanto ¹, Wening Lestari ¹ , Herlan Setiawan ¹ , Titis Sekar Humani ¹ *

Cited by CrossRef: 4

1- Shah A, Dabhade A, Bharadia H, Parekh P, Yadav M, Chorawala M. Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects. 2024;79(9-10):235 [Crossref]

2- Lunj S, Smith T, Reeves K, Currell F, Honeychurch J, Hoskin P, Choudhury A. Immune effects of α and β radionuclides in metastatic prostate cancer. Nat Rev Urol. 2024;21(11):651 [Crossref]

3- Belge Bilgin G, Bilgin C, Orscelik A, Burkett B, Thorpe M, Johnson D, Johnson G, Kallmes D, Sartor O, Kendi A. Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis. Ann Nucl Med. 2024;38(11):865 [Crossref]